Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06783192 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)
A Phase 1 study of Human Immunodeficiency Virus (HIV) and HIV Pre-exposure Prophylaxis, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT06783192 is a Phase 1 study of Human Immunodeficiency Virus (HIV) and HIV Pre-exposure Prophylaxis that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 14 participants, below the 508-participant average among 18 other Human Immunodeficiency Virus (HIV) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06783192, a Phase 1 study of Human Immunodeficiency Virus (HIV) and HIV Pre-exposure Prophylaxis, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to assess the effect of a single dose of MK-8527 on the single-dose pharmacokinetics (PK) and the safety and tolerability of levonorgestrel/ethinyl estradiol (LNG/EE) in healthy adult postmenopausal or ovariectomized female participants.
Conditions Studied
Interventions
- DRUG MK-8527
- DRUG LNG/EE
Study Locations (1)
Florida
- QPS-MRA, LLC-Early Phase (Site 0001) - South Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2023-08-14 |
| Est. Completion | 2023-10-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06783192
The ClinicalTrials.gov registry entry for NCT06783192 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 508-participant average among 18 other Human Immunodeficiency Virus (HIV) trials with a reported enrollment target (97% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Human Immunodeficiency Virus (HIV) appearing as the primary indexed condition, and to 2 interventions - of which MK-8527 is the first listed.
NCT06783192 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06783192 about?
NCT06783192 is a clinical study titled "A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)". This study is designed to assess the effect of a single dose of MK-8527 on the single-dose pharmacokinetics (PK) and the safety and tolerability of levonorgestrel/ethinyl estradiol (LNG/EE) in healthy adult postmenopausal or ovariectomized female participants.
What is the current status of trial NCT06783192?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2023-08-14. Estimated completion is 2023-10-11.
What conditions does trial NCT06783192 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus (HIV), HIV Pre-exposure Prophylaxis.
What interventions are being tested in trial NCT06783192?
The interventions under investigation include: MK-8527 (DRUG), LNG/EE (DRUG).
Who is sponsoring clinical trial NCT06783192?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06783192 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus (HIV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children
COMPLETED · Phase 1
-
Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults
COMPLETED · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1
COMPLETED · Phase 1
-
Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)
COMPLETED · Phase 1
-
Persuasive Health Communication Intervention for HIV/HCV
RECRUITING · NA
-
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
RECRUITING · NA
Explore more on PlainTrial
Human Immunodeficiency Virus (HIV)
All registered trials for this condition
HIV Pre-exposure Prophylaxis
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.